
    
      This is a randomized, two arm clinical trial. The investigators performing the primary and
      secondary endpoints are blinded to subject identifiers and arm identifiers.

      Subject's screening for HCV Genotype 4 started in Agouza Hospital in July 2010 and ended in
      February, 2011. No recruitment has occurred for HCV Genotype 1.
    
  